Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$42.51 - $63.78 $7.63 Million - $11.5 Million
-179,601 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$45.3 - $60.27 $8.14 Million - $10.8 Million
179,601 New
179,601 $10.2 Million
Q3 2020

Nov 13, 2020

SELL
$47.45 - $62.95 $6.16 Million - $8.17 Million
-129,832 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$46.85 - $61.05 $3.09 Million - $4.03 Million
-66,018 Reduced 33.71%
129,832 $7.66 Million
Q1 2020

May 15, 2020

SELL
$41.6 - $63.4 $1.99 Million - $3.03 Million
-47,841 Reduced 19.63%
195,850 $9.26 Million
Q4 2019

Feb 14, 2020

SELL
$53.85 - $65.27 $4.36 Million - $5.28 Million
-80,958 Reduced 24.94%
243,691 $14.7 Million
Q3 2019

Nov 14, 2019

SELL
$59.06 - $72.15 $146,645 - $179,148
-2,483 Reduced 0.76%
324,649 $19.5 Million
Q2 2019

Aug 14, 2019

SELL
$62.09 - $86.14 $17.6 Million - $24.5 Million
-284,030 Reduced 46.47%
327,132 $21 Million
Q1 2019

May 15, 2019

BUY
$52.92 - $81.17 $1.12 Million - $1.72 Million
21,152 Added 3.59%
611,162 $49.6 Million
Q4 2018

Feb 14, 2019

BUY
$43.37 - $59.54 $4.24 Million - $5.83 Million
97,870 Added 19.89%
590,010 $31.9 Million
Q3 2018

Nov 14, 2018

SELL
$42.88 - $53.7 $94,636 - $118,515
-2,207 Reduced 0.45%
492,140 $25.4 Million
Q2 2018

Aug 14, 2018

BUY
$40.53 - $50.7 $18.3 Million - $22.9 Million
451,883 Added 1064.16%
494,347 $20.6 Million
Q1 2018

May 15, 2018

BUY
$44.08 - $55.05 $27,197 - $33,965
617 Added 1.47%
42,464 $1.87 Million
Q4 2017

Feb 14, 2018

SELL
$50.3 - $64.39 $33,399 - $42,754
-664 Reduced 1.56%
41,847 $2.11 Million
Q3 2017

Nov 14, 2017

BUY
$45.56 - $59.57 $22,597 - $29,546
496 Added 1.18%
42,511 $2.16 Million
Q2 2017

Aug 14, 2017

BUY
N/A
42,015
42,015 $2.14 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.35B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track First Light Asset Management, LLC Portfolio

Follow First Light Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First Light Asset Management, LLC with notifications on news.